# Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma

> **NCT02986451** · PHASE2 · WITHDRAWN · sponsor: **Sun Yat-sen University**

## Conditions studied

- Relapse/Refractory Multiple Myeloma

## Interventions

- **DRUG:** clarithromycin
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02986451
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-12
- **Primary completion:** 2018-12
- **Final completion:** 2019-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2018-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02986451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02986451, "Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02986451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*